DDW: Tysabri (natalizumab) Demonstrates Fast Sustained Response in Crohn's
30th May 2006, 20:07 GMT
LOS ANGELES — Patients with moderate to severe Crohn's disease had a significant response to initial infusion with Tysabri (natalizumab) and at eight weeks, researchers reported here.
DDW: Tysabri (natalizumab) Demonstrates Fast Sustained Response in Crohn's related news:
- Bridge: Bidding quiz — Accent
- Fast food to blame for Caribbean's lack of fast bowlers — Cricinfo cricket news
- Hot line needs fast response — The Honolulu Advertiser: Local News
- CORRESPONDENCE: Natalizumab for Relapsing Multiple Sclerosis — New England Journal of Medicine
- SACP 'deeply disturbed' by Cabinet's comments — Mail & Guardian Online
- The GOOD fast food guide — the Mail online | Health
- SRF Global Translations Special: $98 Blog Post and Response Translation — B.L. Ochman's weblog - Internet and corporate blogging strategy, and online marketing trends, with news and commentary
- Author: Fast food industries prey on teens — Dave McGurgan
- Laxman leads Indian response — Cricinfo cricket news
- A Russian doctor demonstrates a box with vaccine against bird ... — Bird flu on Yahoo! News Photos
Latest news from MedPage Today Cardiovascular:
- AHA: Women Receive Less Cardiovascular Secondary Prevention
- AHA: Chest Protectors Have Fatal Flaws in Blocking Cardiac Arrest
- AHA: No Cardiovascular Benefit from Folic Acid and B Vitamins
- AHA: Attention from Pharmacist Improves Compliance for Older Patients
- AHA: Non-Invasive Office-Based Test Could Increase Appropriate Use of ICDs
- AHA: Human Atrial Natiuretic Peptide May Reduce Reperfusion Injury
- AHA: Blood Test Improves Management of Acute Heart Failure
- AHA: Novel Drug Effective for Hyponatremia in Heart Failure Patients